SCHEMBL450628

SCHEMBL450628

COc1ccc(-n2c(C(C)CNS(=O)(=O)c3ccc(C(C)(C)C)cc3)nc3ccccc3c2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 1/20 0.46
RAB9A P51151 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PDE10A Q9Y233 3/20 0.44
CXCR3 P49682 2/20 0.44
PTGS2 P35354 1/20 0.44
TSHR P16473 1/20 0.44
PPARG P37231 1/20 0.43
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
G6PD P11413 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580933 0.90 HRH3 (0.50) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL451472 0.85 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL448784 0.84 PDE10A (0.49) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL451205 0.81 CXCR3 (0.50) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL449419 0.79 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL1554168 0.79 PTGS2 (0.42) ALDH1A1MEN1KMT2ACYP1A2CYP2D6
SCHEMBL450629 0.78 ALDH1A1 (0.48) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL450032 0.77 ALDH1A1 (0.64) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL1552961 0.74 CXCR3 (0.54) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL452486 0.74 GAA (0.67) ALDH1A1MEN1KMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US disclosed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885MEN1 4424/4885KMT2A 3861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.